Microscopic Polyangiitis
📧 Sign up to get email alerts when something new happens for Microscopic Polyangiitis.
Sign up freeTop drugs studied for this disease
-
EMA withdrawal · 2026-08-21EMA Revoked: Tavneos (avacopan) — Vifor Fresenius Medical Care Renal Pharma France
The EMA revoked Tavneos (avacopan) for its indications, including Microscopic Polyangiitis and Wegener Granulomatosis, effective January 15,…
-
EMA withdrawal · 2026-08-19EMA Revoked: Tavneos (avacopan) — Vifor Fresenius Medical Care Renal Pharma France
The EMA revoked Tavneos (avacopan) authorization for indications including Microscopic Polyangiitis and Wegener Granulomatosis.
-
EMA withdrawal · 2021-08-16EMA Withdrawn: Ritemvia (rituximab) — Celltrion Healthcare Hungary Kft.
EMA withdrawal of Ritemvia (rituximab) by Celltrion Healthcare Hungary Kft., affecting indications in lymphoma (non-Hodgkin) and vasculitic …
-
EMA withdrawal · 2020-06-24EMA Application withdrawn: Rituximab Mabion (rituximab) — Mabion Spolka Akcyjna
The EMA application for Rituximab Mabion (rituximab) by Mabion Spolka Akcyjna has been withdrawn.
-
EMA withdrawal · 2019-07-08EMA Withdrawn: Rituzena (previously Tuxella) (rituximab) — Celltrion Healthcare Hungary Kft.
EMA withdrew Rituzena (rituximab) from the market (formerly Tuxella), with the decision dated 28 January 2019.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS withdrawal · 2015-07-30Clinical Trial Update: BIANCA-SC: A Study of the Efficacy, Safety, and Tolerability of Blisibimod in Addition to Methotrexate During Induction of Remission in Subjects With ANCA-Associated Small Vessel Vasculitis [Phase 2]
A Phase 2 trial evaluating blisibimod added to methotrexate for induction of remission in ANCA-associated small vessel vasculitis (granuloma…